pagiantmetknicksfan@yahoo.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hear that merger and acquisition folks are getting up early in the morning these days trying to strategize about keeping Elite's stock price down so they can accumulate shares.....LOL LOL
That is what is so funny about the arguments. Even if an efficacy test is required, no one can give any reason why it wouldn't pass. The Oxy beads are separate.....it is a generic drug. They know the plasma profile and those trials proving that have been stellar. Elite can make generic drugs. And we know the Naltrexone beads don't leak as well. So while there is no common sense reason to do an efficacy trial, no one can give legitimate reasons to fear one.
I hear that merger and acquisition folks are getting up early in the morning these days trying to strategize about keeping Elite's stock price down so they can accumulate shares.....LOL LOL
Earnings are only going to continue to increase and top line will too obviously
Almost a $100m a year company now and turned profitable
We expect to report net revenues for the three months ended September 30, 2014 of approximately $23 million compared to approximately $400,000 for the same period in 2013. We also expect to report net income for the three months ended September 30, 2014 of approximately $400,000 versus a net loss of approximately $100,000 for the same period in 2013.
There still is no Embeda and that is truly LOL LOL....regardless what you posted below about ADT is blatantly incorrect. And Elite doesnt have to be better or worse. Just has to be and there is no reason it won't be.
No one seems to be able to give me a legitimate reason why it won't pass any study required by FDA. So any arguments against are only trying to convince of a longer possible timeline even though that does not seem that likely either.
Those that have done the research can only really come to one conclusion. Elite will have an approved line of Opioids or the company will get bought out. That is the end game regardless of the arguments to and fro.
Maybe because these are different concepts, one with embedding a bead inside a bigger bead. You know the one that been approved so many times but gets recalled and retested because they can't seem to get a stable batch or some other odd reason....and still no launch
What is there to learn from running efficacy trials on a multi bead system? And no one had come up with any reason why Elite would obviously not pass any efficacy trials if they were needed. It is a generic drug. The Naltrexone has already been proven to be sequestered in the current trials. Opioid generics relieve pain and based on blood plasma it is being released at the same rates as the reference drug.
What is really scaring LOL....is that that what Elite is doing here is so modular. Once one domino falls, in this case Oxy, all the rest fall right behind it. Potential to be truly ground breaking. Simple and better concept of an accepted scientific approach.
Yeah....the FDA is looking to deter what it can. Thus Elite's approach is similar to Pfizer and Purdue....you know the approved drug concepts. Neither of which stop oral abuse. But we already knew all of that.
Can you smell a drug filing here shortly.....hmmmmmmm
It is licensing revenues. It is clear as day in the filings
License fee revenue up a ridiculous %. Almost $2m just in this revenue for the Q. Looks like things are actually happening after all.
NEWS WOW!!!! MMRGlobal Reports Record 3rd Quarter Revenue Increase of More Than 1,500%
http://money.cnn.com/news/newsfeeds/articles/marketwire/1158632.htm
MMRGlobal, Inc. (OTCQB: MMRF) ("MMR" or the "Company"), a leading provider of Personal Health Records, MyEsafeDepositBox storage solutions and electronic document management systems for consumers and healthcare professionals, today filed its quarterly financial report on Form 10-Q for the period ended September 30, 2014 with the United States Securities and Exchange Commission. The Company announced a 1,584% increase in revenues for the third quarter of 2014, as compared to the third quarter of 2013. During the quarter, the Company recorded revenues of $1,896,271, and gross profit of $1,807,311. The Company also reported cash on hand of $1,491,510 at the end of the quarter. The Company's quarterly revenues were driven by licensing and other sources and represent the highest quarter in MMR's history. The Company also announced that in 2014 it will report its biggest year since its inception. For the nine months ended September 30, 2014, the Company reported revenues of $2,437,095 as compared to $535,146 for the same period last year, an increase of 355.4%. Net cash provided by operating activities for the nine months ended September 30, 2014 was $226,382, compared to net cash used of $2,174,399 in the similar period in 2013.
According to Robert H. Lorsch, Chairman and CEO, "In a letter to shareholders in April this year, the Company projected that 2014 would be 'our year' and after this quarterly filing, it appears that it is." The Company's nine month revenues are already 72% higher than 2011's 12-month revenues, which was previously the Company's largest year reported, and 75% higher than 2012 and 2013 revenues combined.
As the health insurance industry goes into open enrollment season, and Healthcare.gov launches its second year along with statewide exchanges, more and more consumers are becoming aware of the importance of having and maintaining a Personal Health Record ("PHR") in order to better manage their health and healthcare costs. Having a PHR enables individuals and their families to be prepared in the event of a medical emergency or other disaster; and by taking control of their family's health, a PHR can help avoid unnecessary or duplicate medical tests and expenses.
There is a growing emphasis on patient empowerment and Personal Health Records, which is the primary focus of the Company's business. In this post-Affordable Care Act environment, America is counting on having millions of newly insured patients, who require Health IT solutions to coordinate care and control costs. Supported by government initiatives, healthcare providers, employers, insurers, and retail pharmacies and clinics are seeking ways to optimize health through health information technology and MMR's solutions do this easily and cost-effectively.
MMR, a practicing entity and provider of Personal Health Record products and services, also owns and licenses worldwide health information technology patents and other intellectual property rights. Through its wholly owned subsidiary, MyMedicalRecords, Inc., the Company has a Health IT patent portfolio consisting of 13 issued U.S. patents, 17 pending U.S. applications, and numerous issued patents and pending applications in other countries or regional authorities of commercial interest including Australia, Singapore, New Zealand, Mexico, Japan, Canada, China, Hong Kong, South Korea, Israel and Europe. MMR's issued U.S. patents currently include U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; 8,321,240; 8,498,883; 8,626,532, 8,645,161; 8,725,537; 8,768,725 and 8,775,212, as well as additional applications and continuation applications involving inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. The most recently issued patent, U.S. Patent No. 8,775,212, represents MMR's first Clinical Trials patent and includes 18 claims directed to methods and systems that provide for self-reporting being used to create Electronic Health Records for purposes including Clinical Trials.
Although MMRGlobal's primary focus is as a provider and licensor of Health IT products and services, the Company acquired a patent portfolio of biotechnology assets as a result of a reverse merger with Favrille, Inc., a biopharmaceutical company, in January 2009. Favrille invested more than $100 million in research and development on its FavIdâ„¢/Specifidâ„¢ vaccine trials to treat B-cell lymphoma, which also includes extensive data from the vaccine trials and thousands of patient tumor samples. Additionally, the Company has a growing list of patents related to its anti-CD20 monoclonal antibodies under the title, "Antibodies and Methods For Making and Using Them," issued in the United States, Mexico, Australia and South Korea with patents pending in the U.S., Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan and Korea.
About MMRGlobal, Inc. MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavIdâ„¢/Specifidâ„¢ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.
Forward-Looking Statements All statements in this release that are not strictly historical facts are "forward-looking statements." Such forward-looking statements are based on MMR's current assumptions, beliefs and expectations, and involve risks, uncertainties and other factors that may cause MMR's actual results to be materially different from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words such as "expect," "plan," "possibility," "offer," "if," "negotiate," "when," "believe," "will," "estimate," "continue," and similar expressions. Risks, uncertainties, and other factors that could cause or contribute to such differences include, but are not limited to: ongoing and future intellectual property enforcement actions; the ability to successfully litigate or settle claims of patent infringement; MMR's ability to develop, license and monetize its patent and the additional patents in the portfolio for both MMR's Health IT and biotechnology IP assets; reliance upon the successful operations of its business partners in selling MMR's products and services, the timing of milestone payments in connection with licensing its IP; MMR's ability to obtain necessary financing, generate sufficient cash flow, and maintain appropriate indebtedness; and the increasing development of market competition in the area of electronic records in clinical trials. These factors and others are described in more detail in MMR's public filings with the Securities and Exchange Commission, including the risks discussed in the "Risk Factors" section in MMR's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of these reports can be found on MMR's website (www.mmrglobal.com) under the heading "Investor Relations." MMR is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Yep. Folks are loading and have been....That is in the charts.
After reading the posts tonight, it is looking pretty obvious that ELTP is about to go on a run....
I chose the opposite of what you have stated here. So far I am up an incredible amount of money following that plan.
So they approved it before. Say how come it hasnt launched again and again and again?
Good. Most of the time I find that when analyst opinion come out, the stock has come close to plateauing....I heard the same arguments when the stock was .04, .07...
WHen it is $1 I hope no analysts give coverage then either...Means they are still accumulating
Same concept just a better mousetrap in Eli 200,....
Embeda is just not a stable platform. I dont really care if it launches or not. I kind of assumed it had actually....LOL LOL
Actually that is more misinformation, if they file end of year and launch next year the stock price will be many x what it is today. As far as revenue to launch many many art products to generate billions in revenue, there will be partners lining up at the door. Actually we know there is plenty of interest now but not selling out cheap obviously.
Yes. Very exciting times since that one drug makes the stock a 5-10x on your investment here. Embeda launching finally gets you nothing really on your investment.
So you are saying that no drug launches are occurring? That doesnt make any sense. A drug launch is a one time event so they are not occurring. So if a drug launches now, it would be occurring but only really the day it launches. SO really what you are saying is that no drug launched today. I agree but some are definitely due to launch. Thanks for reminding us.
I do expect them to launch shortly.
How many times has it been approved then? Interestingly how many years since the first time? 4 years, 5 years, 6 years?
I lost track really. Like I said, I thought it was already being marketed but pretty funny that it isn't again....
I lost track. I just assumed it was being marketed to see it had to be re-approved again. I lost track how many times it has been approved....Didnt you say before it was about to launch? What happened there?
I kept hearing that Embeda was about to launch...LOL LOL
Saying it has been approved really isn't news since it has happened many times...LOL LOL
It would appear you are correct. Pretty funny how some kept saying it is about to launch, it is a about to launch but still hasnt....Neither is it a threat to Elite nor is it real competition....still pretty funny
Its been re-approved like 5 times. I do think it is good actually as noted before but pretty funny how long it is taking. Its a bad approach to a good idea....but helps Elite...
Holy crappola.....Embeda still delayed....lol
Nah...depends on who is buying and why and if there are synergies and timing and then there is the time and cost it may take to move. Plus drugs and trials are contingent on where they were made or there are delays. Lots of things happen all the time. Elite will wait for the best price for us though.
Well that is a good point. All the proprietary stuff is with Elite too. The trial drugs were made there. The API validated there etc....
Remember when Actavis and Watson essentially merged? Many of the effects there were two years down the road if memory serves based on the agremements.
Buyout wouldnt change this. They would still be running the programs...that is how it works....And a partnership would be the same
I took all the PRs as positive. And now the largest bank in Niger is backing this to close. Doing business in Africa is complicated to say the least but it is so full of massive opportunity especially in safe places like Niger. Seems this small cap company is in the mix for an incredible amount of business and closing contracts and getting deposits with major bank funding. Then they are announcing more deals and potential massive deals on top of that...
Then there is all this container and other business. You are ultimately looking at net revenues greater then the cap on an annual basis meaning you are looking for 5-10 times PPS just based on current deals we know about....
Heck, they keep announcing new very profitable deals as it is....
An no dilution or any of that typical OTC nonsense.
It almost seems that people can't or don't want to believe the deal is actually closing....and that there is more much occurring on top of it....Heck they announced another 15m deal today.....
I do too
You and I don't always see things the same way for sure but here on PXYN so far in total agremeent. The question about todays PR lies in the details but it is the obvious step needed to take this company to the next level which is to be wildly profitable....It probably is profitable now but this potentially takes the top off of it.
shhhhhhh.......lol
You mean the positive trial results....lol
This patent was final rejected before, a year ago...if you don't even know why it was rejected again, or for what the patent is even for....
You do realize that "Final Rejection" does not really mean it is actually final rejected too...don't you???
Serious question. Can anyone here tell me a good reason why Elite's Eli series of drugs would not pass any of the trials?
All these negative posters but can anyone tell me any real reason why?
The current trials proved the Naltrexone doesnt leak
The current trials proved the essentially generic drug delivers the correct amount of the opioid.
So can anyone tell me why the trials would fail?
One of the four table legs? Please explain what the patent is about then...lol lol..Does it have any bearing whatsoever on anything? why?
LOL HAHAHAHAHAHAHAHA....I am not the one that posted it....hahahahahaha
So tell us what this bad news is about if it has any bearing whatsoever on Elite right now....LOL LOL